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COFACTOR OF BRCA1 PROMOTES EPITHELIAL-MESENCHYMAL-TRANSITION
AND CELL PROLIFERATION IN INTERMEDIATE STAGE HEPATOCELLULAR
CARCINOMA CELL LINE

ABSTRACT
Hepatocellular carcinoma ranks as one of the most lethal types of cancer worldwide and
in Egypt. Being complex and heterogenous clinically and molecularly, HCC has a very
poor prognosis, and it lacks adequate diagnostic and prognostic molecular markers.
Cofactor of BRCA1 (COBRA1); also known as NELF-B, is one of the NELF complex
components that stalls RNA polymerase II during transcription elongation and regulates
several processes in the cell. Previous studies have shown the upregulation of COBRA1
in Hepatocellular carcinoma (HCC) compared to healthy liver tissue. It was also shown to
support cell proliferation and migration in early stages of HCC. In our study, we
investigated the role of COBRA1 in the epithelial-mesenchymal transition (EMT)- a critical
process in cancer metastasis, and progression of HCC. Functional analysis was done by
silencing the expression of COBRA1 in an intermediate stage HCC cell line SNU449,
followed by examining the effect of the knockdown on some cancer hallmarks. COBRA1
knockdown cells showed decreased cell proliferation, induction of apoptosis,
accompanied by a downregulation of Ki67, Survivin that mark for proliferation and antiapoptosis respectively. Moreover, COBRA1 Knockdown cells showed a decrease in cell
migration and invasion, accompanied by decreased expression of TWIST1- one of the
key transcription factors that mediate EMT. Our results demonstrated that COBRA1
supports cell proliferation, migration and invasion, and inhibits apoptosis, which implicates
it has a critical role in the progression of HCC.
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1.Introduction
1.1. Hepatocellular Carcinoma
1.1.1. Incidence and epidemiology
Liver cancer ranks second among the leading causes of cancer deaths, accounting for
788,000 death cases in 2015, with around half to one million newly diagnosed cases
every year (1,2). Less developed regions have an incidence of almost 95% of worldwide
incidence, and 96% of all mortality (3). In Egypt, liver cancer is the most common type of
cancer among men, and the second common among women, and the first in both,
accounting to 23% of all diagnosed cancer cases (4). Liver cancer is a male predominant
cancer, with an incidence ratio of almost 4:1 between men and women (5). There are
several types of primary liver cancers, among which hepatocellular carcinoma (HCC)
represents 85-90% of the cases (6). The occurrence of HCC is the highest at the age of
70 years and above, with rare occurrence at ages younger than 40 (7).

1.1.2. Etiology and risk factors
Several risk factors predispose to the occurrence of HCC, major ones include; Hepatitis
B virus (HBV) and Hepatitis C virus (HCV) infections, aflatoxins consumption, and
alcoholism. Other factors that also increase the risk of HCC include obesity, diabetes and
non-alcoholic fatty liver (8). The chronic active exposure to the different HCC risk factors
cause insult to the liver cells, which is usually accompanied by chronic inflammation,
hepatocytes necrosis, formation of fibrotic tissue, and liver cirrhosis. Cirrhotic liver is
closely related to HCC, where around 80% of HCC arise in livers that are either cirrhotic
or chronically inflamed (9).
HBV and HCV infections alone associate with 75% of the diagnosed cases worldwide,
and HBV has double the contribution of HCV (10). In Egypt where HCV prevalence is the
highest worldwide affecting 14% of the population (11,12), HCV is estimated to
1

predispose to around 40-50% of HCC cases, with a decline in HBV associated HCC to
25% of the cases (13,14). That decline in HBV-associated HCC could be attributed to the
introduction of obligatory HBV vaccination, and the higher incidence of HCV nationally
(15).
The mechanisms by which the risk factor mediates hepatocarcinogenesis are variable.
HBV infection is viewed by many authors as the most potent factor among them (16).
HBV is a DNA virus, it mediates carcinogenesis through several mechanisms that include
and not limited to; 1- integration of its genomic DNA into the host genome, causing
genomic instability. 2- Causing DNA insertional mutations that disrupt genes involved in
processes like cell proliferation, cell cycle, and differentiation. 3- Production of a protooncogene HBx , that transforms in hepatocytes, to bind to p53 inhibiting DNA repair and
cell apoptosis. HBx has also been reported to activate cell signals that induce cell
proliferation (17,18,19).
HCV is an RNA virus, it doesn’t integrate into the host genome, however it produces
proteins that directly or indirectly induce mechanisms like liver fibrogenic and survival
pathways, affect immunity interactions and metabolism (20). It also induces mutations by
causing double-stranded DNA breaks (21).
Aflatoxin consumption as well is considered one of the major risk factors to HCC,
especially in countries with humid and warm climates, where environment is suitable for
fungal growth. Aflatoxin is a mycotoxin which is produced by fungus such as Aspergillus
flavus, that grow on foods like peanuts, rice and corn, especially when improperly stored.
(22). Aflatoxins produce very potent mutant metabolites inside the body, that cause DNA
damage and accumulation of mutations. It was found to cause mutations in p53 gene,
tumor suppressor regulating DNA repair and cell apoptosis, and that mutation has been
reported in around 30-60% of HCC cases in regions known to be aflatoxin-endemic
(23,24). There is growing evidence that aflatoxin consumption in Egypt is becoming one
of the major risk factors (15). Evidences of interaction between HBV-Aflatoxin have been
reported, which augments their risk of HCC development (25,26,27). Chronic alcohol
consumptions attributes to liver damage through causing an oxidative stress, and
endotoxin induced inflammation (28).
2

1.1.3. HCC molecular pathogenesis
Advancement in the next generation sequencing technologies resulted in huge progress
into understanding the genetic and epigenetic alterations associated to the process of
hepatocarcinogenesis. Molecular alterations include somatic mutations of genes that play
key roles in carcinogenesis such as telomerase promoter and p53. As discussed earlier,
different etiologies can contribute to the occurrence of certain mutations. Dysregulation
of several critical cellular pathways was also found to be frequently altered in HCC, which
include pathways regulating signaling of growth factors such as insulin like growth factor
(IGF) and hepatocyte growth factor, others involved in cell differentiation such as Notch
and Wnt pathways, and pathways related to angiogenesis as well. Molecular alterations
in HCC were not limited to genetic ones only, but also epigenetic modifications were
discovered that include changes in DNA methylation, histone modifications, chromatin
remodeling, and changes in the regulating non-coding RNAs; microRNAs and long noncoding RNAs (29).

1.1.4. Surveillance and diagnosis
HCC is asymptomatic, and mostly diagnosed at late stages. Due to increased awareness,
and implementing active surveillance, diagnosis at earlier stages has increased recently.
Screening every 6 months is recommended for high risk patients, especially those who
have cirrhosis (30). Screening tools include ultrasound and measuring Alpha-fetoprotein
(AFP) levels serum levels (31). AFP has been shown not to be very useful lately, as it
doesn’t necessarily correlate to tumor growth (32). Ultrasound detects 85-90% of tumors
ranging between 3-5 cm in size, and that ability decreases to 60-80% for tumors less than
1 cm in size (33,34). Other imaging techniques like magnetic resonance imaging (MRI)
and computed tomography (CT) scan can be employed to further investigate smaller
undetectable lesions. Uncommon or unclear features detected by imaging may require
the use of an invasive image guided biopsy, which can give many false-negative results
(35).

3

1.1.5. HCC molecular markers
The lack of ideal molecular biomarkers caused the dependence of the current surveillance
tools on the morphological features, and serological AFP levels that lack sensitivity and
selectivity, which makes detection of HCC at very early stages not always possible.
Identification of sensitive and specific molecular markers for diagnosis, prognosis and
monitoring of therapy is inadequate, and can change the face of HCC management.
Extensive research is currently done, aiming for setting molecular classification and
profiling of HCC different stages, and even etiologies, in attempts to identify novel
biomarkers that can be used in diagnosis and prediction of prognosis (36,37).

1.1.6. Treatment
There are several treatment options available for HCC, and the choice of regimen
depends on stage at which patient is diagnosed. Several staging systems exist, among
which the Barcelona Clinic Liver Cancer (BCLC) classification is the most used and most
efficient tumor staging system, as it takes into account the stage of the tumor, the patient
performance status, and the liver function reserve, which are factors that impact the
appropriate choice of treatment (5,38). Curative therapies include liver transplantation,
and tumor resection which are applicable at early stages, also locoregional treatment
options like radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) can
be used at early stage. For intermediate stages; transarterial chemoembolization (TACE)
and radioembolization are used. Recently, systemic molecular targeted agents started
emerging for treatment of advanced HCC. Sorafenib is currently available in the market,
and others are still under investigation (39,40,41). Even with the availability of various
treatment options, HCC poor prognosis persists, with less than 5% 5-year survival rate,
as most patients are diagnosed at stages at which they are no longer eligible for curative
therapy (42).

Liver transplantation is considered as the best treatment option for patients with cirrhotic
liver, as it doesn’t only eliminate the tumor, but the underlying disease as well. Eligibility
4

for transplantation is determined by a set of criteria referred to as Milan criteria; liver has
one lesion 5 cm or smaller or has a maximum of 3 lesions that are 3 cm in size or smaller.
Following Milan criteria results in a 75% 5-year overall survival rate, and less than 15%
recurrence rates (43-44). To extend the use of liver transplantation as it is the most
effective treatment approach, some centers either expand Milan criteria, or use some
local treatments like RFA and TACE to downsize the tumor size prior transplantation (41).
Despite the effectiveness of liver transplantation, the procedure is limited by the
availability of donor organs, as patients wait for long periods to receive the transplant,
through which their disease deteriorates (45).
Tumor surgical resection is recommended for patients that have single nodules, with
properly functional liver that is not cirrhotic (46). However, it has a very high recurrence
rate that reaches 50-80% within the first 5 years, that can be attributed to the emergence
of a new tumor in the diseased liver or due to dissemination from the resected tumor (5,
42).
For early stage tumors that are not suitable for surgery, RFA is the standard ablative
therapy, replacing percutaneous ethanol ablation as it has shown better survival rates
and local control. RFA can create necrotic areas of size up to 3 cm (41).
For management of intermediate stage of HCC where tumors are unresectable, TACE is
considered as the standard of care, at which chemotherapy is injected into the segmental
branches feeding the tumor and was shown to increase survival and delay tumor
progression (47). Radioembolization is another emerging therapy suggested for
intermediate stage HCC, that is under development and optimization (48,49,50).
Despite the thorough and advanced studies on HCC, we are still far from having a clear
understanding of its molecular pathogenesis. This difficulty is attributed to the high
complexity and heterogeneity of the molecular mechanisms. More studies are needed to
characterize pathways involve in the initiation and progression of HCC, which will facilitate
the development of targeted therapies and biomarkers for diagnosis and prognosis.

5

1.2. Cofactor of BRCA1
Cofactor of BRCA1 (COBRA1) also known as NELF-B, is a leucin enriched 580 amino
acid protein, that has three LXXLL motifs. It was first isolated and identified in 2001 as a
novel protein that interacts with BRCA1 via yeast two hybrid screen (51).
Not before long, COBRA1 was found to be identical to the NELF-B, a subunit of the
negative elongation factor (NELF) complex, a four-subunit complex that interacts with
other factors to pause the transcriptional activity of RNA polymerase II (RNAPII), and
regulates several important processes in the cell (52). COBRA1 lacks DNA binding
domain in its structure, so it always mediates its gene expression regulatory roles through
interacting with other factors, that are not limited to BRCA1 or NELF. COBRA1 was found
to interact with various transcription factors such as Activator protein-1 (AP-1), and
nuclear receptor such as Estrogen receptor-alpha (ERα), progesterone receptor B (PRB),
Glucocorticoid receptor (GR), and androgen receptor (AR).
The interaction of COBRA1 with several transcription complexes postulates its
importance in regulating vital cellular processes. Roles and interactions of COBRA1, in
addition to its effect in cancer will be thoroughly discussed below.
1.2.1. Interactions and roles
1.2.1.1. COBRA1, as cofactor of BRCA1
Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene, its
mutations/dysregulation are highly associated to the ovarian and breast cancer
predisposition.it has been shown to regulate multiple processes such as DNA repair and
gene transcription (53,54,55). A study that was performed to elucidate the mechanism of
BRCA1 action, and to identify the co-factors it recruits to initiate large scale chromatin
unfolding. This study employed yeast two-hybrid screen, through which a novel protein
was found to interact with BRCA1, that was then named cofactor of BRCA1 (COBRA1).
COBRA1 was found to be recruited by the first BRCT repeat of BRCA1 to the
chromosome site, and it also showed having independent ability of chromosome
unfolding (51).
6

1.2.1.2. The NELF complex:
Couple of years after the identification of COBRA1, a study of the NELF complex subunits
revealed that COBRA1 is the NELF-B subunit of NELF (52). The NELF complex
recruitment takes place along with DRB sensitivity-inducing factor (DSIF), to mediate
pausing of transcriptional elongation via binding to RNA polymerase II (56,57). NELF
regulates a substantial number of genes that are involved in metabolism, cellular stress
response, proliferation and cell cycle control (58). In vivo studies demonstrated that
NELF-B is essential in early embryogenesis, as its knockout was embryo lethal (59).
NELF complex is composed of 4 subunits; NELF-A, NELF-B, NELF C/D and NELF-E that
are essential for the formation of a functional complex. NELF-C and NELF-D have a
similar structure and are thought to represent translation variants of the same mRNA, and
only either of them would exist in the formation of a NELF complex. NELF-B and NELFC/D form the core of the complex that brings together the other two subunits. NELF-A
binds directly to RNAPII through its RNAPII binding domain, and NELF-E contains an
RNA binding domain, through which it binds to the RNA (52).
In contrast to the initial view of the RNAPII pausing as a transcriptional repressor, several
studies have shown that in many genes, NELF mediated RNAPII stalling has a positive
role in transcription regulation (60,61). The mechanism was first demonstrated in a study
at which NELF was depleted in Drosophila cells, and microarray analysis showed the
downregulation of most of the NELF regulated genes. Further investigation showed that
this positive role was facilitated through maintaining a permissive chromatin structure by
NELF, to enhance gene expression (60).

1.2.1.3. COBRA1 as corepressor of Steroid hormone receptors
Steroid hormone receptors are a group of transcription factors that bind to DNA and
activate gene expression in a legend-dependent or independent manner, and the potency
of their activity is mostly determined by the availability of the cognate hormones and a set
of transcription co-regulators (62,63,64). COBRA1 displayed transcriptional co-repressor
7

role, by binding to ERα and repressing the expression of its downstream targets in breast
cancer cell line (65). Further studies were done to elucidate the effect of COBRA1 on
other steroid hormone receptors. COBRA1 was found to have a very high affinity to
androgen receptor (AR), and less affinity to glucocorticoid receptor (GR), while the least
affinity detected was to progesterone receptor B (PRB). Knockdown of COBRA1 showed
a remarkable enhancement of expression of AR transcriptional activity, and a moderate
effect on GR and PR. This study did not only denote the negative effect of COBRA1 in
regulating steroid hormone receptor-dependent transcription, but has also showed
COBRA1 dual role as it is also involved in alternative splicing of the regulated genes (66).
The interaction between COBRA1 and the steroid hormone receptors goes in line with
the presence of 3 LXXLL motifs identified in its structure, as that motif is frequently found
in transcription coregulators of steroid hormone receptors (51).

1.2.1.4. Interaction with AP-1 complex
In addition to the Interaction of COBRA1 with NELF subunits and BRCA1, it was also
found to interact with a transcription factor; AP-1 and regulating its transcriptional activity.
Ectopic expression of COBRA1 was found to inhibit AP-1 transcriptional activity, while
COBRA1 knockdown enhanced AP1 activity (67). AP-1 complex was reported to promote
cell survival, and in other context it was found to induce apoptosis. It also regulates genes
involved in differentiation, proliferation, and neoplasm formation (68).

8

1.2.2. Role of COBRA1 in Cancer
COBRA1 involvement in several major transcription regulation machinery has been
demonstrated, regulating many critical cellular pathways. That suggested the potential
role COBRA1 could play in a disease like cancer. However, COBRA1’s role in
carcinogenesis is still unclear, and has only been studied in breast, gastrointestinal, and
liver cancers.

1.2.2.1. COBRA1’s role in breast cancer

COBRA1’s potential role in cancer was first studied in breast cancer. That was first
demonstrated by Aiyar et al in 2004, where COBRA1 was found to bind to ER-α
repressing its transcriptional activity. That was elucidated by knockdown of NELF
proteins, that resulted in enhancement of cell proliferation mediated by ER-α transcription.
This study showed that this regulation was mediated through RNAPII stalling (65).
COBRA1 transcriptional regulatory role in breast cancer occurs in both estrogendependent and estrogen-independent manner. A huge overlap between the genes
regulated by BRCA1 and COBRA1 was identified, of which many are involved in breast
cancer progression (69,70). All these evidences of the potential role of COBRA1 as a
tumor suppressor in breast cancer from in vitro studies were further confirmed by
examining its levels in breast carcinoma tissues. Low levels of COBRA1 detected on
mRNA levels, were highly correlated to breast cancer metastases and recurrence, and
predicted poor prognosis (71).

1.2.2.2. COBRA1’s role in upper gastrointestinal cancer

Contradictory to what was shown in breast cancer, COBRA1 was found to be upregulated
in

the

majority

of

upper

gastrointestinal

adenocarcinomas (UGC).

COBRA1

overexpression was highly correlated to downregulation of TFF1, a protein that is
normally expressed in upper gastrointestinal system, and its loss is associated to gastric
9

tumorigenesis. The study demonstrated that COBRA1 negatively regulates AP-1 complex
activation of TFF1 promoter, causing the downregulation of TFF1. It also showed that
regulation of AP-1 complex by COBRA1 in gastric cancer cells is estrogen independent,
unlike breast cancer. This study demonstrated the oncogenic potential of COBRA1 in
UGCs for the first time and highlighted that COBRA1’s role in cancer is cancer-type
dependent (72).

1.2.2.3. COBRA1 in hepatocellular carcinoma

Owing to the potential role of COBRA1 in cancer demonstrated in breast and UGC, and
our interest in understanding molecular pathogenesis of HCC, we studied COBRA1 for
the first time in HCC at our lab. Levels of COBRA1 were found to be upregulated in HCC
tissue samples compared to their adjacent non-neoplastic liver samples. The same
pattern of COBRA1 overexpression was obtained through in silico analysis of HCC
microarray database. In silico analysis has also demonstrated an overexpression in the
other NELF subunits, with NELF-E showing the highest differential expression. This
pattern of NELF subunits simultaneous deregulation is consistent with their
interdependent nature reported previously (73).
The levels of COBRA1 was also evaluated among five cell lines representing different
stages of HCC and a control. Results have shown highest levels of expression at early
HCC stages, with a gradual decrease as the stages advanced, with significant
downregulation in high grade HCC cell line (74). To investigate the role of COBRA1 in
HCC, loss of function analysis was performed using HepG2 Cell line that represents an
early stage of HCC. Knockdown of COBRA1 was achieved using short interfering RNA
(siRNA), and cells showed a significant decrease in proliferation and migration. That was
also accompanied by down regulation in Ki-67 the standard proliferation marker, and
Survivin, a key anti-apoptotic protein that is overexpressed in most cancers. (73)

10

HYPOTHESIS AND SPECIFIC OBJECTIVES
COBRA1 is involved in transcriptional regulation of numerous genes, being an important
component of key transcription complexes. An overexpression pattern of COBRA1 was
found in hepatocellular carcinoma, and it was shown to support cell proliferation and
migration in early HCC stages. Therefore, we hypothesis it has a key role in the
progression of hepatocellular carcinoma. To evaluate this hypothesis, we had the
following as our main objectives:
1-To optimize and achieve an efficient COBRA1 knockdown using short interfering RNA
in intermediate stage hepatocellular carcinoma cell line SNU449.
2-To analyze the effect of COBRA1 knockdown on major cancer hallmarks; cell
proliferation, apoptosis, migration and invasion.
3-To examine the differential gene expression of some key players in cancer on mRNA
level upon COBRA1 knockdown.

11

2.MATERIALS AND METHODS
2.1. Cell Culture
SNU449 cell line was used in all experiments. The cell line was a generous gift from
Dr.Mehmet Ozturk at the Department of Molecular Biology and Genetics, Bilkent
University, Turkey. SNU449 represents an intermediate stage of HCC, grade II-III/IV. The
cell line was derived from a 52 years old, Asian male. Hepatitis B viral DNA was detected
in the cell line (75). Cells were used at passage numbers 15-25 in all experiments, in their
logarithmic growth phase. Cells were cultured in RPMI 1640 (Lonza) media,
supplemented with 10% FBS (Invitrogen), 100 units/ml penicillin and 100mg/ml
streptomycin (Invitrogen). Cells were incubated at 37°C and supplied with 5% CO 2 in a
humidified incubator. Inverted microscope (Olympus IX70, USA) was used to observe
cells.

2.2. Trypan Blue Exclusion Test for Cell Viability

Trypan blue method was used to determine viable cell count. 20µl of Cell suspension was
mixed with equal volume of 0.4% trypan blue in phosphate buffer Saline (PBS). Viable
cells were counted using hemocytometer (Hausser Scientific). Ten microliters of cell
suspension were loaded in each chamber, and cells in the four outer squares of each
chamber were counted. Cell count per ml was determined using the following equation:
Cells number /ml= Total number of viable cells/total number of squares x dilution factor x
10,000.

2.3. Gene Silencing
For COBRA1 knockdown, we utilized a pool of 4 siRNAs that target different exons of
COBRA1 mRNA (siGENOME SMARTPool; M-015839-02, Dharmacon). Table 1 showing
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exon numbers and target sequences of COBRA1 siRNAs (siCOBRA1). Allstars negative
control siRNA (SI03650318, Qiagen) was used as a control to the siRNA Transfection
procedure effect. Negative siRNA (siNTC) in non-targeting has no homology to
mammalian genes (76). All siRNAs were reconstituted using RNase-Free water, to a
concentration of 20µM, according to manufacturer instructions.

Table 1. COBRA1 siRNAs, their target sequences, and their corresponding exons:

siRNA Target Sequence (5’-3’)

Target exon

1

CCGAAAGCUUCACUAAGUU

9&10

2

GCGACUUGGCCUUUGGCGA

11

3

GAGCCUGGGACAUGAUCGA

8

4

CGUCUAAGCUGGAGGCGUU

12

SiGENOME SMARTPool (M015839-00)

2.4. siRNA Transfection
COBRA1 knockdown was performed by reverse transfection of COBRA1 siRNA into
SNU449 cells using Lipofectamine3000 (Life technologies), that facilitates the delivery of
siRNA into the cells through the cell membrane by forming liposomes that carry the
siRNA. Optimized Transfection conditions were done in 6 well plates. Controls used;
Untreated cells cultured in 1.5 ml RPMI 1640 supplemented with FBS and 0.5 ml of OPTIMEM (Gibco) media, Mock cultured in the same media in addition to lipofectamine, and
Negative siRNA control. For transfection of COBRA1 and negative SiRNA, 500 microliters
of OPTI-MEM media were transferred to a 1.5 ml Eppendorf tube, 40nM (4 microliters of
the 20µM stock solution) siRNA were added to the Opti-mem media and mixed with 3.75
microliters of lipofectamine 3000 by pipetting. siRNA and lipofectamine3000 were
incubated for 15-20 at room temperature minutes to promote complex formation. siRNA
-Lipofectamine mix was then transferred to the corresponding wells, at which 1.5 ml of
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antibiotic-free media (RPMI+10% FBS) containing 1.5 x 10 5 cells approximately. Growth
media were changed 24 hours post-transfection. Cells were harvested 96hrs posttransfection for RNA and Protein analysis. All Transfections were performed in an RNase
free environment. Evaluation of knockdown efficiency was performed by analyzing the
proteins levels of COBRA1 using western blot analysis.

2.5. RNA Extraction
RNA extraction was performed using Trizol reagent (Invitrogen, USA) according to the
manufacturer’s recommendations. RNA was dissolved in nuclease-free water, and
RNase free conditions were maintained during the procedure. RNA was quantified using
SPECTROstar Nano by measuring absorbance at 260 nm, purity was estimated by
obtaining 260/280 ratio, and RNA quality was assessed using RNA integrity gels.

2.6. Reverse Transcription Polymerase Chain reaction(RT-PCR)
Semi-Quantitative RT-PCR was used to analyze the differential gene expression. 0.5 µg
of the total RNA was reverse transcribed using random primers in a total volume of 20µl,
using RevertAid First Strand cDNA synthesis kit (Thermo Scientific, USA), according to
the manufacturer’s protocol.
PCR was performed using MyTaq DNA Polymerase kit (Bioline). One µl of cDNA was
used per PCR reaction. GAPDH was used as an internal control. PCR conditions were
similar among all analyzed genes except for the cycle numbers and annealing
temperatures listed in Table (2); 94°C for 3 minutes, followed by cycles of (94°C for 30
secs, annealing temperature for 30 secs, and 72°C for 45 secs), followed by 7 minutes at
72°C for final extension. PCR products were run on a 2.5% agarose gel and visualized
by Gel Doc EZ System (Bio-Rad, USA).
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2.7. Western Blot Analysis
Protein was extracted from cells for Western blotting using ice-cold 1xLaemmli Lysis
buffer (50 mM Tris pH6.8, 2% sodium dodecyl sulfate, and 10% glycerol), supplemented
by 1x Halt protease inhibitor cocktail (ThermoScientific, USA) (10µl of the protease
inhibitor for 1ml Laemmli Lysis buffer). For 6 well plate, cells from each well were
extracted using 80-100 µl of the extraction buffer, by pipetting several times, followed by
an incubation period of 30-40 minutes at 4°C with shaking.

Table 2. RT-PCR Primers sequences, annealing temperature, number of cycles, and
amplicon sizes (F: forward primer, R: reverse primer, bp: base pair):

Gene

Primer sequence (5’-3’)

Name
GAPDH

F: CCACCCATGGCAAATTCCATGGCT

Annealing

Cycle

Amplicon

Temperature

Number

size (bp)

60.5 °C

26 cycles

598

59.5°C

32 cycles

366

60˚C

27 cycles

199

61˚C

28 cycles

R: TCTAGACGGCAGGTCAGGTCCACC
COBRA1

F: ACATCACCAAGCAGAGGAA
R: GATCCAGCTGTTCCAGCTTC

Ki67

F: CTTTGGGTGCGACTTGACG
R: GTCGACCCCGCTCCTTTT

Survivin

F: TTGAATCGCGGGACCCGTTGG

(BIRC5)

R: CAGAGGCCTCAATCCATGGCA

Isoform 1: 477
Isoform 2: 359
Isoform 3: 546

NELF-A

F: GTCGGCAGTGAAGCTCAAGT

60˚C

32 cycles

250

56˚C

28 cycles

443

63˚C

28 cycles

565

60°C

37 cycles

126

R: TTCACACTCACCCACCTTTTCT
NELF-C/D

F: GAAGAAGGAGAGACCCCAGC
R: GTGCCCAAGGCTAGTGTGAT

NELF-E

F: TGGTGAAGTCAGGAGCCATCAG
R: CGCCGTTCAGGGAATGAATC

TWIST1

F: AGCTACGCCTTCTCCGTCTG
R: CTCCTTCTCTGGAAACAATGACA
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To eliminate viscosity through denaturing, a heating step for 5 minutes at 90 °C was done,
if viscosity persists, more buffer was added. Samples were centrifuged at 12,000 rpm for
20 minutes at 4°C, and the supernatant was collected in a fresh vial. Protein was
quantified using BCA Protein Assay kit (Pierce Biotechnology, USA) according to the
manufacturer’s protocol.

20-30 µg of whole cell lysate proteins were mixed with 4x-SDS-Laemmli with loading dye
to give a final volume of 28 µl and boiled for 5 minutes at 99°C. Samples were loaded on
to 10% SDS-Polyacrylamide gel. After protein separation on SDS-Polyacrylamide gel,
proteins were blotted on to a nitrocellulose membrane. To block the membrane,
membranes were soaked in 5% non-fat dry milk in 1x TBST (0.01% Tween in TBS buffer)
for 1 hour at room temperate. Afterward, membranes were incubated with primary
antibodies overnight at 4°C. Membranes were then washed 3 times (5minutes each)
using 1X TBST, then incubated for 1 hour with the secondary antibody at room
temperature. Membranes were subsequently washed 3 times (5 minutes each) using
1XTBST, followed by addition of 2 ml of BCIP/NBT Phosphatase colorimetric substrate
(KPL) for 1-5 minutes (depending on the bands color development). Upon the
development of bands, membranes were washed using distilled water to stop the color
development. Membranes were visualized using Gel Doc EZ system (Bio-Rad, USA).

Primary antibodies used; anti-GAPDH (Abcam, ab8245) (1:10,000 in 5% non-fat dry milk),
anti-COBRA1 (Abcam, ab167401) (1:1000 in 3% non-fat dry milk). Secondary antibodies
used are anti-mouse (KPL, 4751-1806) (1:10,000 in 5% non-fate dry milk), and anti-rabbit
(KPL, 4751-1516) (1:10,000 in 5% non-fat dry milk). All non-fat dry milk used was
dissolved in 1XTBST.
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2.8. Wound Healing Assay
Wound Healing Assay was performed to assess the effect of knockdown on cell migration
rate. Transfection process was performed in 24-well plate as described before in section
2.4., after downscaling all quantities of reagents used to 1/5 of the original amounts to
suit the well size. At 96 hours post-transfection, media was aspirated, and two
perpendicular scratches were generated in the confluent (~90% confluent) cells
monolayer using the sterile 20 µl yellow tip. Cells were then washed gently twice with
PBS to remove floating cells and cell debris, and fresh media were added. Pictures at
different fields of the wound were taken at two timepoints from wound generation ( 0 and
24 hours from scratch generation) using an inverted microscope. Wound area was
measured using ImageJ Software. Percentage of wound closure was calculated using the
following equation:
Percentage wound closure= [(wound area 0 hr-wound area 24 hr)/ wound area 0hr] x 100

2.9. Transwell Invasion Assay

To test the effect of COBRA1 knockdown on cell invasion, we used the Transwell invasion
assay. Cells were collected 96-hours post-transfection, and 2x105 cells of COBRA1
knockdown and negative control cells were suspended in 100 µl RPMI1640 media
supplemented with 1% FBS. Cells were applied to the top chamber of 24-well cell culture
insert (GBO) with pore size 8µm. Cell culture inserts were coated with 40µg of Collagen
I (SERVA, 47254), left to dry in the incubator overnight and were rehydrated with media
30 minutes before applying the cells. The lower chamber of the 24-well plate contained
600 µl RPMI1640 media supplemented with 10% FBS. Cells were incubated in the
chambers for 22 hours, cells in the upper side of the chamber were removed, then cells
that migrated to the lower side of the chamber were fixed with 4% formaldehyde and
Stained with DAPI (KPL,71-03-01) (1:1000 in PBS). Cells were visualized using
fluorescent microscopy at 200X magnification. Cells in 5 random fields were counted for
each condition, and average numbers of invading cells were compared.
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2.10. Data Analysis
For PCR and Western Blot Differential gene expression analysis, ImageJ software was
used to quantify the bands’ intensities, and bands were normalized to loading control
GAPDH. Relative gene expression was presented as fold change to either Untreated
control, or the Negative siRNA Control.
Data were presented as the mean value ± Standard deviation (SD) from two independent
experiments, unless specified otherwise. Unpaired Student’s t-test (two-tailed) was used
to determine statistical significance for pairwise comparison. GraphPad Prism 5.0
software was used to perform multiple experimental groups comparisons by One-way
ANOVA, followed by a Bonferroni post-test. p-value less than 0.05 was considered
significant (*p-value ≤ 0.05, ** p-value ≤ 0.01, *** p-value ≤ 0.001).
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3.RESULTS
3.1. Optimization of COBRA1 knockdown in SNU449
Different conditions and methods of knockdown were tested in the process of knockdown
optimization, to achieves efficient knockdown that would promote the aimed functional
analysis. Two methods of siRNA transfection: Forward and Reverse, different siRNA
concentrations and different incubation periods were tested. The efficiency of knockdown
was estimated on protein level by Western blot analysis.
siRNA is known to mediate transient silencing of the targeted gene by promoting the
degradation of its mRNA hence preventing translation. Upon the degradation of siRNA,
the target gene starts going back to its expression levels. Incubation period required for
optimal knockdown vary according to each cell line and gene, and usually range from 4896 hours.
The concentration of the siRNA employed requires optimization, to obtain an efficient
knockdown, with the minimal amount of siRNA. Excessive amounts of siRNA can cause
an off-target activity, at which mRNAs other than the targeted are being degraded.
3.1.1. Forward transfection:

For forward transfection, cells were seeded one day prior to the addition of the siRNAlipid transfection complex.
3.1.1.a) Duration of incubation:
To test the efficiency of transfection at different incubation time points, forwards
transfections were done using 25nM of siRNA, and harvested at 48, 72, and 96 hours.
Knockdown was maximal at 72 hours (Figure 1.A). For subsequent optimization trials,
cells were incubated for 72 hours.
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3.1.1.b) siRNA concentration:
Three different concentrations were tested; 25nM, 40nM and 60nM. Cells were incubated
for 72 hours post-transfection, then harvested for protein analysis. Lowest protein levels
were obtained by the 25nM, while higher concentrations didn’t show enhanced
knockdown efficiency (Figure 1.B.). However, maximum knockdown levels obtained by
forward transfection weren’t very high, and further optimization was carried on to test
whether higher knockdown levels could be obtained by employing reverse transfection.
3.1.2. Reverse Transfection
To further optimize COBRA1, reverse transfection was performed, at which cells are
seeded during transfection and mixed with the siRNA-lipid complex as a cell suspension
before adhering to the cell culture plate. Two different concentrations; 25nM, and 40nM
were tested, at two different incubation periods; 72, and 96 hours (Figure 1.C.). Optimum
knockdown was obtained by using 40nM siCOBRA at 96 hours incubation period with
only 4% COBRA1 residual protein expression. The optimum knockdown conditions were
performed on all the subsequent experiments used for further analysis.

3.2. Estimation of COBRA1 knockdown efficiency on mRNA level, and its
effect on cell morphology
Optimum transfection conditions resulted in a significant protein knockdown (p-value ≤
0.001) with an average of 96% decrease in protein expression (Figure 2.a.). mRNA levels
of COBRA1 were also analyzed to estimate the transfection efficiency on mRNA level,
and a significant decrease in expression was obtained (p-value ≤ 0.01), with an average
of 93.5% decrease (Figure 2.b.). Images of transfected, (mock, negative siRNA- siNTC,
and COBRA1 siRNA- siCOBRA1) and untransfected cells were compared to observe
whether the knockdown effects on cell morphology (Figure 3). No significant change in
morphology was noticed, however, COBRA1 knockdown cells were less dense than the
other three controls, which could be due to decreased cell proliferation or cell survival
upon knockdown (Figure 3).
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A

B

C

Figure 1 Optimization of COBRA1 knockdown transfection conditions in SNU449. Western
blot assay employed for determining COBRA1 protein expression levels among different
optimization conditions. A) Forward transfection, different incubation periods: using 25nM siRNA
concentration, testing different incubation periods (48, 72, and 96 hours). Silencing was highest
at 72 hours. B) Forward transfection, different siRNA concentrations:

25nM, 40nM, 60nM,

incubated for 72 hours. Maximum knockdown was achieved by 25nM concentration; higher
concentrations did not achieve enhanced silencing efficiency. C) Reverse Transfection: testing
two different concentrations (25nM, and 40nM), and two different incubation periods (72 and 96
hours). Maximal knockdown was obtained by 40nM siRNA concentration, and 96 hours
incubation. All bands were quantified by ImageJ and normalized to GAPDH as an internal control,
presented as fold change to untreated control samples.
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A

B

Figure 2. COBRA1 siRNA transfection significantly knocks down COBRA1 on protein and
mRNA levels. A) Effect of COBRA1 siRNA knockdown on protein level compared to the negative
siRNA control. All bands were quantified by ImageJ and normalized to GAPDH as an internal
control, presented as fold change to siNTC. Statistically significant at *** p<0.001 (Student t-test,
two-tailed). B) Effect of COBRA1 siRNA knockdown on mRNA level. All bands’ intensities were
analyzed using ImageJ software and normalized to GAPDH the internal control, presented as fold
change to negative siRNA (siNTC) control. Presented data represent mean ±SD of two
independent experiments (n=2). Statistically significant at ** p<0.01 (one-way ANOVA,
Bonferonni’s post-test).
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Figure 3. No Change in morphology was observed upon transfection and knockdown of
COBRA1, but cells were less in density. Images of untreated, mock, siNTC and siCOBRA1
were obtained at 200X magnification. Morphology seemed comparable between different controls
and COBRA1 knockdown cells; however, COBRA1 knockdown cells seemed less dense than the
controls used.
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3.3. COBRA1 knockdown significantly downregulates the expression of
NELF-A, and does not affect NELF-C/D or NELF-E expression
The effect of COBRA1 knockdown on the expression levels of the other NELF subunits
was measured by semiquantitative RT-PCR (Figure 4). No significant difference was
noticed in the expression levels of NELF-C/D or NELF-E. NELF-A, on the other hand,
was significantly downregulated (p-value ≤ 0.001) with an average of 30% decrease
(Figure 4).

3.4. COBRA1 Knockdown significantly decreases cell count and expression
of proliferation marker Ki67
The number of cells 96-hours post-transfection was calculated using the Trypan blue
exclusion assay, to determine the effect of COBRA1 knockdown on cell proliferation. A
significant decrease (p-value ≤ 0.05) in cell count due to COBRA1 knockdown was
estimated, by an average of 55% decrease in cell count compared to siNTC negative
control (Figure 5A). No significant change in cell count was shown among the controls
(Untreated, mock and siNTC).
For additional examination of the effect of COBRA1 on cell proliferation, the levels of Ki67
gene expression were estimated using RT-PCR. Ki67 was significantly decreased (pvalue ≤ 0.05) by an average of 51% compared to siNTC (Figure 5B).
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Figure 4. Significant downregulation of NELF-A expression upon COBRA1 knockdown,
and no effect on NELF-C/D, NELF-E expression levels. The effect of COBRA1 knockdown
on NELF subunits expression on mRNA levels was assessed using RT-PCR. No significant
effect was noticed in NELF C/D, or NELF-E. NELF-A, on the other hand, was significantly
downregulated. All bands were quantified using ImageJ, normalized to GAPDH as an internal
control, and represented as fold change to Negative (siNTC) control. Data represent the mean
of two independent experiments (n=2). Statistically significant at *** p ≤0.001(one-way ANOVA,
Bonferonni’s post-test).
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A

B

Figure 5.

COBRA1 significantly reduces cell proliferation and downregulated the

expression of Ki67 A) Cell proliferation was determined by counting the cells after 96 hours of
the transfection using the Trypan blue exclusion assay. Untreated, Mock and siNTC cells showed
comparable cell counts, while siCOBRA1 showed a significantly lower cell count relative to the
siNTC control. Data presented as the mean ±SD (n=2) of the cell count relative to the siNTC,
statistically significant at * p≤0.05 (one-way ANOVA, Bonferonni’s post-test). B) The Effect of
COBRA1 knockdown on the Ki67 expression on mRNA levels was assessed using RT-PCR. Ki67
was significantly downregulated compared to siNTC. All bands were quantified using ImageJ,
normalized to GAPDH as an internal control, and represented as fold change to Negative siNTC
control. Data represent the mean of two independent experiments (n=2). Statistically significant
at * p ≤0.05 (Student t-test, two-tailed).
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3.5. COBRA1 knockdown suppresses the mRNA expression of Survivin and
induces apoptosis
Survivin is a member of the Inhibitor of apoptosis proteins and is highly overexpressed in
most types of cancers, inhibiting apoptosis and supporting cell cycle progression (77).
Survivin has been previously shown to be affected by the COBRA1 knockdown in the
early stage HCC cell line the HepG2 (73). We wanted to test if this correlation is consistent
with more advanced HCC stages. Our results show a significant downregulation (p-value
≤ 0.001) in Survivin mRNA levels by an average of 53% compared to the siNTC (Figure
6). Significant downregulation was observed only in the wild type variant of Survivin (477
bp), while a decrease in Survivin-deltaex3 (369 bp) was found to be non-significant. The
third variant that could be detected by the primers we used; Survivin-2B (546 bp) was not
expressed in our cells.
Upon staining the Cells with DAPI stain to visualize the nuclei, fragmented nuclei were
observed in COBRA1 knockdown cells and not the siNTC control, which marks for cell
apoptosis (Figure 9).

Figure 6. COBRA1 knockdown significantly downregulates the expression of Survivin The
Effect of COBRA1 knockdown on Survivin expression on mRNA levels was assessed using RTPCR. Survivin was significantly downregulated compared to siNTC. All bands were quantified
using ImageJ, normalized to GAPDH as an internal control, and represented as fold change to
Negative siNTC control. Data represent the mean of two independent experiments (n=2).
Statistically significant at *** p ≤0.001 (Student t-test, two-tailed).
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3.6. COBRA1 knockdown decreases cell migration
Classical wound healing assay was performed to test the effect of COBRA1 knockdown
on cell migration. The wound was created at 96 hours post-transfection, and pictures were
taken for the wound at 0 hours of its creation, and at 24 hours. Percentage of wound
closure was calculated by measuring the area of the wound at the two mentioned time
points. The cell migration rate significantly (p-value ≤ 0.01) decreased in COBRA1
knockdown cells, showing around 45% decrease in migration rate compared to the siNTC
negative control (Figure 7).

Figure 7. COBRA1 knockdown significantly decreases cell migration rate. Wound healing
assay was used to assess the effect of COBRA1 knockdown on cell migration. The wound was
created at 96-hours post transfection and monitored over 24 hours. Changes in wound area were
analyzed by ImageJ software and percentage of wound healing was calculated in both siCOBRA1
and siNTC. Data presented as the mean ±SD (n=2) of the change in migration rate relative to the
siNTC, statistically significant at ** p<0.01 (Student t-test, two-tailed).

3.7. COBRA1 knockdown decreases cell invasion
Transwell invasion assay was used to assess the effect of COBRA1 knockdown on cell
invasion through extracellular matrix (ECM). 96 hours post-transfection, cells were moved
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to cell culture insert covered by a layer of collagen and incubated for 22 hours. The
number of cells that could invade through collagen decreased by around 43% upon
COBRA1 knockdown compared to siNTC (Figure 8).

Figure 8. COBRA1 knockdown decreases cell invasion. Transwell assay was used to assess
the cell invasion ability through collagen. Invasive cells were fixed, stained by DAPI, and
visualized by fluorescent microscopy at 20X magnification. COBRA1 knockdown cells showed
around 43% decrease in the number of invasive cells compared to siNTC.
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Figure 9. Detection of fragmented nuclei in COBRA1 knockdown cells marking for cell
apoptosis. Cells nuclei were stained with DAPI and visualized by fluorescent microscopy. Some
fragmented nuclei were detected in COBRA1 knockdown cells, which is a marker of apoptosis.

3.8. COBRA1 knockdown suppresses the expression of transcription factor
TWIST1
Cell invasion and migration that occur during cancer progression are mediated through
epithelial-mesenchymal transition (EMT) process. Many transcription factors mediate this
process, TWIST1 is one of the main transcription factors that mediate EMT in HCC. We
tested the expression levels of TWIST1 using RT-PCR, and a significant downregulation
(p-value ≤ 0.05) by an average of 42% was detected upon COBRA1 knockdown
compared to siNTC (Figure 10).
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Figure 10. COBRA1 knockdown significantly downregulates the expression of TWIST1 The
Effect of COBRA1 knockdown on the TWIST1 expression on mRNA levels was assessed using
RT-PCR. TWIST1 was significantly downregulated compared to siNTC. All bands were quantified
using ImageJ, normalized to GAPDH as an internal control, and represented as fold change to
Negative siNTC control. Data represent the mean of two independent experiments (n=2).
Statistically significant at * p ≤0.05 (Student t-test, two-tailed).
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4.DISCUSSION
Hepatocellular carcinoma is a disease of very aggressive course and poor prognosis.
Being asymptomatic at its early stage, and lack of appropriate diagnostic markers,
contribute to its late diagnosis, at stages where surgical resection/transplantation are
mostly non-applicable or non-efficient. There is also lack of effective prognostic and
molecular biomarkers for monitoring treatment efficiency, which makes recurrence rates
one of highest.
HCC molecular heterogeneity and complexity make it difficult to characterize the
molecular machinery attributing to its development and progression. The thorough study
of the underlying molecular mechanisms, and discovery of key player biomarkers will not
only provide better diagnostic and prognostic markers but will also promote the
development of effective targeted therapies.
In our lab, a potential biomarker was studied for the first time in HCC; COBRA1, also
known as NELF-B. It is a part of transcription regulatory machinery that attributes to the
regulation of several important processes in the cell. The role of COBRA1 was previously
studied in breast and UGC cancers, and showed opposite roles, signifying its
tissue/context-dependent function.
In HCC, we found it to be upregulated compared to their paired non-neoplastic tissue,
and it was also found to support proliferation and migration at early stages of HCC (73).
As an extension to our previous work, we aimed to determine its role in maintenance and
progression of HCC at more advanced HCC stages. To achieve that, we performed a loss
of function analysis by transient silencing of COBRA1 in an intermediate stage HCC cell
line; SNU449, followed by an analysis of the effect of that on some of the main cancer
hallmarks, and expression of some of the well-characterized biomarkers in cancer.

4.1. Co-regulation among NELF subunits
NELF consists of four subunits; NELF-A, NELF-B, NELF-C/D, NELF-E, that are all
essential for the assembly of the functional complex. They are characterized by being
interdependent, as the knockdown of any of them results in the downregulation of the
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other subunits via post-transcriptional modifications, exclusively (61,58,71). Upon
examining the mRNA levels of NELF subunits post- COBRA1 knockdown, we detected
significant downregulation of NELF-A, which was not reported on the transcriptional level
before, to the best of our knowledge.
Pathologically, the simultaneous dysregulation of more than one NELF subunit was
observed more than once. In breast cancer, COBRA1 and NELF-C/D were
downregulated, and showed an inverse relationship with tumor aggressiveness (71,78).
On the other hand, COBRA1 and NELF-E are upregulated in HCC, with the later
described as a risk factor for recurrence and supporting cell proliferation (78). However,
the overlap of modes of action between those subunits is to be further elucidated.

4.2. COBRA1 supports cell proliferation in SNU449
Sustaining cell proliferation is considered the most fundamental cancer hallmark as
described by Hanahan & Weinberg, where cancer cells can evade the tight regulation of
growth signals. COBRA1 was shown to support cell proliferation at initial stages of HCC
(73). We aimed to examine whether that effect was only required during tumor initiation
only, or for maintenance as well at more advanced HCC stages. Our study revealed a
significant effect of COBRA1 in supporting cell proliferation, and positive correlation with
Ki-67 expression, the most commonly used proliferation marker. Ki-67 is essentially
expressed throughout the different stages of cell cycle, promoting its progression and
maintaining cell proliferation (80). On the contrary, in breast cancer, COBRA1 is inversely
related to cell proliferation (65) which highlights the cancer-type dependent role of
COBRA1.

4.3. COBRA1 inhibits apoptosis and promote HCC cell survival
Apoptosis is programmed cell death, which promotes the maintenance of healthy cells
and tissues, by eliminating old, unhealthy, or unnecessary cells (81,82,83). Apoptosis
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pathways are highly dysregulated in cancer, which promotes the survival of defective
cancer cells. Several stimuli trigger the apoptosis process via activation of caspases,
leading to cell death (82). Survivin, also known as BIRC5, is one of eight members in the
inhibitor of apoptosis proteins family (IAPs), that blocks the apoptosis process via direct
binding to caspases (83). Overexpression of IAPs has been demonstrated in different
cancer types, with survivin being the most overexpressed family member in majority of
tumors, and the most potent antiapoptotic protein studied to date (77). It is undetectable
in most differentiated, adult normal tissues, and expressed at low levels in few (84,85).
The role of survivin in cancer is not limited to its anti-apoptotic activity, but it also promotes
cell proliferation. It was found to supports the progression of the cell cycle at early mitosis,
via binding to the microtubules of the mitotic spindles, protecting them from hydrolysis.
(86,87). Its overexpression in early hepatoma cells showed its interaction with cyclin
dependent kinase 4 (CDK4), leading to G1 arrest counteracting, and phosphorylation of
the tumor suppressor retinoblastoma protein (Rb) (88). It was also found to induce
angiogenesis in tumor stroma, by facilitating the endothelial cells proliferation and
migration, and expression of VEGF (Vascular endothelial growth factor) (89,90).
In our study, a direct correlation was shown between COBRA1 and survivin expression,
as survivin expression was significantly downregulated upon COBRA1 knockdown. The
effect of survivin downregulation as demonstrated in our study, that significantly
decreased in cell number upon knockdown of COBRA1, infers a reduction in cell
proliferation, and increased cell apoptosis, which was confirmed by the detection of
nuclear fragments (91).
Regulation of survivin by COBRA1 has been consistent in early-stage HCC cell line
HepG2, in the intermediate stage HCC cell line (SNU449), and also in the breast cancer
cell line (73, 65). This conserved correlation over different types and stages of cancer
makes the investigation of the exact mechanism by which COBRA1 regulates survivin
very important.
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4.4. COBRA1 promotes Epithelial-Mesenchymal Transition
Epithelial mesenchymal transition (EMT) is the process by which epithelial cells lose their
epithelial phenotype, and acquire mesenchymal phenotype via events of biochemical
changes, to become more invasive, migratory and resistant to apoptosis. This process
normally occurs and is tightly regulated during development, wound healing, and was
found to be also occurring during cancer progression promoting metastasis (92).
The initiation of EMT process and its completion include a series of molecular processes,
where the activation of certain transcription factors suppresses the expression of
epithelial markers and induce the expression of mesenchymal markers. These markers
include expression of specific cell-surface proteins, cytoskeleton proteins reorganization,
and the secretion of the extracellular matrix (ECM) degrading enzyme (93). The changes
that occur during the EMT enable those cells to enter the cascade of invasion-metastasis
through which primary tumors spread to other organs. Metastases cascade comprises;
local invasion, intravasation into blood and lymph vessels, transport and survival through
circulation, extravasation, micrometastases formation, and eventually macroscopic
metastases colonization (94,95,96).
As cancer metastases is a very critical hallmark of cancer progression, the estimation of
the effect of COBRA1 silencing on cell migratory and invasive ability was essential. For
examining cell migration, we used the classical wound healing assay, the standard in vitro
technique for cell migration assessment (97). Our results demonstrated a significant
decrease in cell migration upon COBRA1 silencing, going in line with what was previously
reported for early-stage HCC cell line HepG2 (73), which suggests a similar role
throughout the early and intermediate HCC stages. We also demonstrated the effect of
COBRA1 on cell invasion in vitro as COBRA1 silencing decreased the cells’ ability to
invade through an ECM equivalent. Our results show for the first time in HCC that
COBRA1 supports the invasion and not only migration. These results are contradictory to
what has been previously reported in breast cancer, where COBRA1 inversely correlates
to metastases (71).
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Several transcription factors contribute to the initiation of EMT, among which zinc-finger
transcriptional repressors (SNAIL and SLUG), TWIST and zinc-finger E-box-binding
(ZEB) are considered the main regulators of the process, activated at its early stage (93).
The contribution and co-operation between these transcription factors vary among
different tissues, and they cooperate to repress the epithelial genes, and thus promote
mesenchymal ones (98,99).

4.5. TWIST1 mediates EMT in SNU449
In our study we examined the expression levels of TWIST1, to investigate the possible
mediators of COBRA1 effect on EMT. TWIST1 is a member of the evolutionary conserved
basic loop-helix-loop (BLHL) transcription factors family (100). TWIST1 has an essential
role in development (101), and its role in promoting metastases via EMT is well
established by studies done in various cancer types (102, 103). TWIST1, as well as other
EMT transcription factors (SNAIL and ZEB superfamilies) have an antiapoptotic effect
that is exerted through inhibition of p53, retinoblastoma protein (RB), in addition to other
mechanisms, which benefits the survival of invasive cells through the process of
metastases (104). Apart from its role in metastases, two recent studies on breast and skin
cancer have shown that TWIST1 mediates the development of cancer stem cell
properties, by promoting proliferation and inhibiting apoptosis during tumor initiation. They
showed that TWSIT1 was required at low levels to promote tumor initiation, and higher
levels promote metastases as the tumor progresses, and the tumor initiation property is
mediated via mechanisms independent from EMT, through different downstream targets.
(105,106)

TWIST1 is overexpressed in several types of cancers such as HCC, prostate, gastric, and
breast. It is overexpressed in 43% of primary HCC tumors and correlates to poor
prognosis. A study on EMT regulators in HCC demonstrated that TWIST and SNAIL, not
SLUG were the Key regulators of EMT in HCC. Both were proven to be critical for HCC
EMT/metastases, independently regulated, and have an additive effect. (107)

36

Our study shows downregulation of TWIST1 upon COBRA1 silencing, which goes in line
with the decreased rates of migration and invasion, indicating the role of COBRA1 in
promoting epithelial-mesenchymal transition via TWIST1. However, the effect of
COBRA1 on other EMT transcription factors is yet to be examined to elucidate whether
COBRA1 mediates its effect through TWIST1 only, or through other factors as well.

4.6. Insights about role of COBRA1 and its mode of action
Youssef et al. have previously shown the differential expression of COBRA1 among HCC
cell lines of different stages, with the highest expression levels detected in early stages,
while a gradual decrease of COBRA1 levels was measured as the HCC stages advance
(74). That result could suggest that COBRA1 role is important for HCC initiation, and not
maintenance or progression. To test that hypothesis, we examined the SNU449 cell line
derived from a more advanced HCC tumor, stage II-III/IV. The loss of function analysis
we employed refuted that hypothesis, as COBRA1 was shown to support the progression
of HCC at that stage by mediating several critical cancer hallmarks. However, that needs
further investigation for several reasons; 1- HCC is very heterogeneous in terms of
molecular profile, and that mechanism could be variable among different HCC tumors. 2SNU449 originates from an HBV positive patient, other etiologies of HCC could contribute
differently to the progression of the disease. 3- COBRA1 role in more advanced HCC
stages hasn’t been studied yet, at which it could behave differently.
Through the examination of expression levels of several cancer biomarkers, we found out
that COBRA1 affects the regulation of three important markers of cancer in SNU449 cell
line; TWIST1 reported for the first time to be affected by COBRA1, Survivin and Ki-67,
previously reported in early HCC stage HepG2 cell line. It is worth noting that the three
were downregulated upon COBRA1 knockdown, despite COBRA1 acting predominantly
through the NELF complex that stalls RNA polymerase II at early elongation stages.
Several mechanisms could attribute to these genes’ regulation; they could be indirectly
regulated via transcriptional repressors stalled by the NELF complex, be directly activated
by RNA polymerase stalling, or other unidentified mechanisms. Activation of gene
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transcription via RNA polymerase stalling was first reported by Gilchrist et al. in 2008, in
a study done on Drosophila cells where NELF was silenced and microarray analysis was
performed. Unexpectedly, only one-thirds of the NELF target genes were upregulated,
and the other two-thirds were downregulated. The authors further examined the
mechanism through which NELF mediated its regulation of the downregulated genes and
revealed that polymerase stalling at these genes activates the transcription by sustaining
chromatin accessibility near the promoter-proximal region, while abolishing Polymerase
II contributed to increased nucleosome occupancy (60). The same observation was found
in a study on mammalian breast cancer cells, and the same mechanism was proposed to
be conserved in the mammalian cell (58).
CONCLUSION
In conclusion, our study reveals that COBRA1 plays a vital role in the progression of HCC
in SNU449, supporting critical cancer hallmarks; cell proliferation, inhibition of apoptosis,
migration and invasion. We also showed that COBRA1 positively regulates key players
in these processes; Ki67, Survivin and TWIST1, that is reported to be affected by
COBRA1 for the first time in HCC. These results need further investigations to fully
understand the underlying mechanisms of COBRA1 and need to be extended to more
HCC cell lines of different properties; nonetheless, COBRA1 shows great potential as a
possible therapeutic target and prognostic factor of HCC.
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FUTURE RECOMMENDATIONS
COBRA1 plays key role in HCC initiation and progression. However, that role needs to
be examined thoroughly and extended. Since HCC has different etiologies that affect its
molecular profiles, and due to its heterogeneity in general as a disease, we suggest the
examination of COBRA1 roles in more cell lines of different etiologies, stages, and genetic
backgrounds. Employing techniques such as microarray and RNA seq analysis after gene
silencing will promote a much broader discovery of the genes regulated by COBRA1 and
can dramatically enhance the process of functional analysis. Another tool that is highly
important is in vivo testing of COBRA1 silencing effect using an animal model, as in vitro
testing alone cannot simulate all the physiological factors that interplay with cancer
progression.
To allow a better understanding of the COBRA1 role in promoting EMT, it is worth
examining the levels of transcription factors other than TWIST1 that could promote
metastases in HCC, and more EMT markers such as; E-Cadherin, N-Cadherin, B-Catenin
localization, and matrix metalloproteinases. Also, further investigation of other apoptotic
markers and genes could be valuable to understand how COBRA1 inhibits apoptosis.
We also think that examining the transcriptional regulation mechanisms of the genes
affected by COBRA1, and whether that regulation is direct or indirect is important to give
more insight about the COBRA1 role.
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